Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for improving survival of lymphoma study

Seok Jin Kim, Kihyun Kim, Byung Soo Kim, Chul Yong Kim, Cheolwon Suh, Jooryung Huh, Sang Wook Lee, Jinseok Kim, Jaeho Cho, Gyeong Won Lee, Ki Mun Kang, Hyeon Seok Eom, Hong Ryull Pyo, Yong Chan Ahn, Young Hyeh Ko, Won Seog Kim

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Purpose: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD). Patients and Methods: Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40 to 52.8 Gy and cisplatin 30 mg/m 2 weekly). Three cycles of VIPD (etoposide 100 mg/m 2 days 1 through 3, ifosfamide 1,200 mg/m 2 days 1 through 3, cisplatin 33 mg/m 2 days 1 through 3, and dexamethasone 40 mg days 1 through 4) were scheduled after CCRT. Results: All patients completed CCRT, which resulted in 100% response that included 22 complete responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3% (ie, 22 of 30 responses; 95% CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three cycles of VIPD, whereas four patients did not because they withdrew (n = 2) or because they had an infection (n = 2). The overall response rate and the CR rate were 83.3% (ie; 25 of 30 responses; 95% CI, 65.28 to 94.36) and 80.0% (ie, 24 of 30 responses; 95% CI, 65.69 to 94.31), respectively. Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates were 85.19% (95% CI, 72.48 to 97.90) and 86.28% (95% CI, 73.97 to 98.59), respectively. Conclusion: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.

Original languageEnglish
Pages (from-to)6027-6032
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Issue number35
DOIs
Publication statusPublished - 2009 Dec 10

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Nose
Chemoradiotherapy
Cisplatin
Lymphoma
Radiation
Drug Therapy
Survival
Ifosfamide
Etoposide
Dexamethasone
Neutropenia
Nausea
Disease-Free Survival
Survival Rate
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Seok Jin ; Kim, Kihyun ; Kim, Byung Soo ; Kim, Chul Yong ; Suh, Cheolwon ; Huh, Jooryung ; Lee, Sang Wook ; Kim, Jinseok ; Cho, Jaeho ; Lee, Gyeong Won ; Kang, Ki Mun ; Eom, Hyeon Seok ; Pyo, Hong Ryull ; Ahn, Yong Chan ; Ko, Young Hyeh ; Kim, Won Seog. / Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma : Consortium for improving survival of lymphoma study. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 35. pp. 6027-6032.
@article{d339b7fedc2e493586cf510bf47317dd,
title = "Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for improving survival of lymphoma study",
abstract = "Purpose: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD). Patients and Methods: Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40 to 52.8 Gy and cisplatin 30 mg/m 2 weekly). Three cycles of VIPD (etoposide 100 mg/m 2 days 1 through 3, ifosfamide 1,200 mg/m 2 days 1 through 3, cisplatin 33 mg/m 2 days 1 through 3, and dexamethasone 40 mg days 1 through 4) were scheduled after CCRT. Results: All patients completed CCRT, which resulted in 100{\%} response that included 22 complete responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3{\%} (ie, 22 of 30 responses; 95{\%} CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three cycles of VIPD, whereas four patients did not because they withdrew (n = 2) or because they had an infection (n = 2). The overall response rate and the CR rate were 83.3{\%} (ie; 25 of 30 responses; 95{\%} CI, 65.28 to 94.36) and 80.0{\%} (ie, 24 of 30 responses; 95{\%} CI, 65.69 to 94.31), respectively. Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates were 85.19{\%} (95{\%} CI, 72.48 to 97.90) and 86.28{\%} (95{\%} CI, 73.97 to 98.59), respectively. Conclusion: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.",
author = "Kim, {Seok Jin} and Kihyun Kim and Kim, {Byung Soo} and Kim, {Chul Yong} and Cheolwon Suh and Jooryung Huh and Lee, {Sang Wook} and Jinseok Kim and Jaeho Cho and Lee, {Gyeong Won} and Kang, {Ki Mun} and Eom, {Hyeon Seok} and Pyo, {Hong Ryull} and Ahn, {Yong Chan} and Ko, {Young Hyeh} and Kim, {Won Seog}",
year = "2009",
month = "12",
day = "10",
doi = "10.1200/JCO.2009.23.8592",
language = "English",
volume = "27",
pages = "6027--6032",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma : Consortium for improving survival of lymphoma study. / Kim, Seok Jin; Kim, Kihyun; Kim, Byung Soo; Kim, Chul Yong; Suh, Cheolwon; Huh, Jooryung; Lee, Sang Wook; Kim, Jinseok; Cho, Jaeho; Lee, Gyeong Won; Kang, Ki Mun; Eom, Hyeon Seok; Pyo, Hong Ryull; Ahn, Yong Chan; Ko, Young Hyeh; Kim, Won Seog.

In: Journal of Clinical Oncology, Vol. 27, No. 35, 10.12.2009, p. 6027-6032.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma

T2 - Consortium for improving survival of lymphoma study

AU - Kim, Seok Jin

AU - Kim, Kihyun

AU - Kim, Byung Soo

AU - Kim, Chul Yong

AU - Suh, Cheolwon

AU - Huh, Jooryung

AU - Lee, Sang Wook

AU - Kim, Jinseok

AU - Cho, Jaeho

AU - Lee, Gyeong Won

AU - Kang, Ki Mun

AU - Eom, Hyeon Seok

AU - Pyo, Hong Ryull

AU - Ahn, Yong Chan

AU - Ko, Young Hyeh

AU - Kim, Won Seog

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Purpose: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD). Patients and Methods: Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40 to 52.8 Gy and cisplatin 30 mg/m 2 weekly). Three cycles of VIPD (etoposide 100 mg/m 2 days 1 through 3, ifosfamide 1,200 mg/m 2 days 1 through 3, cisplatin 33 mg/m 2 days 1 through 3, and dexamethasone 40 mg days 1 through 4) were scheduled after CCRT. Results: All patients completed CCRT, which resulted in 100% response that included 22 complete responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3% (ie, 22 of 30 responses; 95% CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three cycles of VIPD, whereas four patients did not because they withdrew (n = 2) or because they had an infection (n = 2). The overall response rate and the CR rate were 83.3% (ie; 25 of 30 responses; 95% CI, 65.28 to 94.36) and 80.0% (ie, 24 of 30 responses; 95% CI, 65.69 to 94.31), respectively. Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates were 85.19% (95% CI, 72.48 to 97.90) and 86.28% (95% CI, 73.97 to 98.59), respectively. Conclusion: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.

AB - Purpose: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD). Patients and Methods: Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40 to 52.8 Gy and cisplatin 30 mg/m 2 weekly). Three cycles of VIPD (etoposide 100 mg/m 2 days 1 through 3, ifosfamide 1,200 mg/m 2 days 1 through 3, cisplatin 33 mg/m 2 days 1 through 3, and dexamethasone 40 mg days 1 through 4) were scheduled after CCRT. Results: All patients completed CCRT, which resulted in 100% response that included 22 complete responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3% (ie, 22 of 30 responses; 95% CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three cycles of VIPD, whereas four patients did not because they withdrew (n = 2) or because they had an infection (n = 2). The overall response rate and the CR rate were 83.3% (ie; 25 of 30 responses; 95% CI, 65.28 to 94.36) and 80.0% (ie, 24 of 30 responses; 95% CI, 65.69 to 94.31), respectively. Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates were 85.19% (95% CI, 72.48 to 97.90) and 86.28% (95% CI, 73.97 to 98.59), respectively. Conclusion: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT.

UR - http://www.scopus.com/inward/record.url?scp=73349087528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349087528&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.23.8592

DO - 10.1200/JCO.2009.23.8592

M3 - Article

C2 - 19884539

AN - SCOPUS:73349087528

VL - 27

SP - 6027

EP - 6032

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -